City
Epaper

Covaxin for Children will take some more time for final approval: Sources

By ANI | Updated: November 8, 2021 17:35 IST

The data for Bharat Biotech's Covaxin for Children, COVID-19 vaccine for children, is under evaluation and the process will take some more time for final approval from the Drugs Controller General of India (DCGI), sources said.

Open in App

The data for Bharat Biotech's Covaxin for Children, COVID-19 vaccine for children, is under evaluation and the process will take some more time for final approval from the Drugs Controller General of India (DCGI), sources said.

"It's a sensitive matter. Data evaluation is underway. More data has been submitted," sources informed ANI.

Recently, the Subject Expert Committee (SEC) had given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's Covaxin COVID-19 vaccine for the beneficiaries aged between 2-18 years.

After evaluation of the data, the final approval will be given by the Drug Controller General of India (DCGI).

Earlier, Bharat Biotech, in an official statement, had said they are waiting for further approvals from the drug regulators.

"This represents one of the first approvals worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of COVAXIN for Children," their statement read.

Bharat Biotech had submitted data from clinical trials in the 2-18 years age group for COVAXIN (BBV152) to Central Drugs Standard Control Organisation (CDSCO).

The data has been thoroughly reviewed by the CDSCO and Subject Experts Committee (SEC) and has provided their positive recommendations, the vaccine maker said.

The Subject expert committee on COVID-19 has already examined the data.

"After detailed deliberation, the committee recommended for grant of market authorization of the vaccine for the age group of 2 to 18 years for restricted use in an emergency situation subject to the setting conditions."

Earlier on November 3, the World Health Organisation (WHO) had also given Emergency Use Listing (EUL) to Covaxin.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Bharat Biotech InternationalDrugs controller general of indiaBharat biotech limitedDrugs control general of indiaBharat biotech international ltdBharat biotech companyGovernment of india department of health and family welfareBharat biotech internationalBharat biotech biotech
Open in App

Related Stories

NationalIndia's First 'Presvu' Eye Drops for Presbyopia Approved by DCGI; Improves Vision in 15 Minutes

NationalCovaxin-Developer Bharat Biotech Amid Reports on AstraZeneca Vaccine, Says ‘Safety Is Primary Focus for All Our Vaccines’

NationalHospitals, blood banks can only charge processing fees for blood, says Government

National"Digital health is very important now...": Bharat Biotech Executive Chairman Dr Krishna Ella at G20 Health Working Group Meet

NationalLicenses of 18 pharma companies cancelled

National Realted Stories

NationalIPS officer Praveer Ranjan assumes charge as CISF DG

NationalAvinash Kumar appointed new Chief Secretary of Jharkhand

NationalFresh low-pressure likely over Bay of Bengal on October 1: IMD

NationalOdisha Minister slams Congress over 26/11 attack response

NationalDelhi HC directs deployment of traffic officials to prevent wrong-side driving at Panchsheel Enclave stretch